Soleo Health secures Qfitlia
By HME News Staff
Updated 2:05 PM CDT, Mon April 14, 2025
FRISCO, Texas – Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first antithrombin-lowering therapy for hemophilia. The U.S. Food and Drug Administration recently approved its use for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B with or without factor VIII or IX inhibitors. "We are pleased to be selected by Sanofi to help bring its first-of-its-kind hemophilia medication to patients,” said Drew Walk, CEO. “Therapies like Qfitlia can have a significant impact on patients living with hemophilia and we look forward to supporting patients who will benefit from this innovative treatment option. Our team continues to work collaboratively with our pharma partners to bring ground-breaking medical treatments to patients to make a meaningful impact on their lives.” Soleo Health has 26 pharmacy locations with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs, and the National Association of Boards of Pharmacy. Additionally, the company operates more than 30 infusion suites and centers throughout the U.S.
Comments